indazoles has been researched along with abemaciclib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Dios, A; Gelbert, LM; Lallena, MJ; Sánchez-Martínez, C | 1 |
| Bang, YJ; Bendell, J; Carlsen, M; Chow, KH; Chung, HC; de Miguel, MJ; Gandhi, L; Italiano, A; Lin, CC; Patnaik, A; Schmidt, S; Su, WC; Szpurka, AM; Vangerow, B; Xu, X; Yap, TA; Yu, D; Zhao, Y | 1 |
1 review(s) available for indazoles and abemaciclib
| Article | Year |
|---|---|
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs.
Topics: Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinase Inhibitor Proteins; Humans; Neoplasms | 2015 |
1 trial(s) available for indazoles and abemaciclib
| Article | Year |
|---|---|
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Benzimidazoles; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Prognosis; Ramucirumab | 2021 |